A Phase 3 interventional study of TR-701 FA and Linezolid in Skin and Subcutaneous Tissue Bacterial Infections, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 118 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.
Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults. Patients are to start treatment with at least 2 IV doses and may receive IV therapy for the entire treatment duration.
Approximately 100 to 140 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment.
The primary objective is to determine the noninferiority (NI) in the early clinical response rate of intravenous (IV) to oral 6 day TR-701 free acid (FA) compared with that of IV to oral 10-day linezolid treatment at 48-72 hours after the first infusion of study drug in the intent-to-treat (ITT) analysis set in patients with acute bacterial skin and skin structure infections (ABSSSI).
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.
First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
• TR-701 FA IV followed by TR-701 FA tablets
Drug: TR-701 FA
• Linezolid IV followed by Linezolid Tablets
Drug: Linezolid
* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion * TR-701 FA Tablets, 200 mg, orally once daily
* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion * Linezolid Tablets, 600 mg, orally every 12 hours
The Early Clinical Response Rate
Responder: No increase in lesion surface area from baseline.
Time frame: 48-72 hours
Clinical Response at the End of Therapy Visit
Responder: No increase in lesion surface area from baseline.
Time frame: Day 11
Clinical Response at the End of Therapy Visit in the Clinically Evaluable at End of Therapy Analysis Set
Responder: No increase in lesion surface area from baseline.
Time frame: End of Therapy Day 11
Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit
Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, and no further antibiotic therapy required for treatment of primary ABSSSI lesion.
Time frame: Post-Treatment Evaluation (7-14 days after the End of Therapy)
Investigator's Assessment of Clinical Success of the Post Therapy Evaluation Visit in Clinically Evaluable-Post Treatment Evaluation Analysis Set.
Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, no new signs, symptoms or complications attributable to the ABSSSI and no further antibiotic therapy required for treatment of primary ABSSSI lesion.
Time frame: Post-Treatment Evaluation (7-14 days after the End of Therapy)
Investigator's Assessment of Clinical Response at the 48-72 Hour Visit
Clinical improvement defined as improvement in overall clinical status.
Time frame: 48-72 Hours
Investigator's Assessment of Clinical Response at the Day-7 Visit
Clinical improvement defined as improvement in overall clinical status.
Time frame: Day 7
Change From Baseline in Patient-reported Pain, by Study Visit
0=no pain, 10=worst pain Only 1 visit per participant for Day 4-6, only 1 visit for Day 7-9, and only 1 visit for Day 10-13.
Time frame: Multiple
| Milestone | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Started | 332 | 334 |
| Completed | 313 | 306 |
| Not completed | 19 | 28 |
| Withdrew: Lost to follow-up | 11 | 14 |
| Withdrew: Randomized but didn't receive study drug | 1 | 7 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Withdrew: Death | 1 | 1 |
Responder: No increase in lesion surface area from baseline.
| participants | Tedizolid Phosphate | Linezolid |
|---|---|---|
| The Early Clinical Response Rate | 283 | 276 |
Responder: No increase in lesion surface area from baseline.
| participants | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Clinical Response at the End of Therapy Visit | 289 | 294 |
Responder: No increase in lesion surface area from baseline.
| participants | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Clinical Response at the End of Therapy Visit in the Clinically Evaluable at End of Therapy Analysis Set | 272 | 280 |
Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, and no further antibiotic therapy required for treatment of primary ABSSSI lesion.
| participants | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit | 292 | 293 |
Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, no new signs, symptoms or complications attributable to the ABSSSI and no further antibiotic therapy required for treatment of primary ABSSSI lesion.
| participants | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Investigator's Assessment of Clinical Success of the Post Therapy Evaluation Visit in Clinically Evaluable-Post Treatment Evaluation Analysis Set. | 268 | 269 |
Clinical improvement defined as improvement in overall clinical status.
| participants | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Investigator's Assessment of Clinical Response at the 48-72 Hour Visit | 304 | 302 |
Clinical improvement defined as improvement in overall clinical status.
| participants | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Investigator's Assessment of Clinical Response at the Day-7 Visit | 309 | 308 |
0=no pain, 10=worst pain Only 1 visit per participant for Day 4-6, only 1 visit for Day 7-9, and only 1 visit for Day 10-13.
| units on a scale | Tedizolid Phosphate | Linezolid |
|---|---|---|
| Day 2 | -1.7 ± 2.05 | -2.1 ± 2.29 |
| Day 4-6 | -3.1 ± 2.67 | -3.3 ± 2.56 |
| Day 7-9 | -4.9 ± 2.89 | -4.9 ± 2.96 |
| Day 10-13 | -5.4 ± 2.80 | -5.6 ± 2.84 |
Collected over Collected from signing of the ICF through the late follow-up visit (up to 38 days).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tedizolid Phosphate | — | 7/331 (2.1%) | 84/331 (25.4%) |
| Linezolid | — | 9/327 (2.8%) | 90/327 (27.5%) |
| Event | Tedizolid Phosphate | Linezolid |
|---|---|---|
| CellutitisInfections and infestations | 0/331 | 2/327 |
| Acute coronary syndromeCardiac disorders | 0/331 | 1/327 |
| Acute myocardial infarctionCardiac disorders | 0/331 | 1/327 |
| Anaphylactic reactionImmune system disorders | 0/331 | 1/327 |
| Meningitis tuberculousInfections and infestations | 0/331 | 1/327 |
| Urinary tract infection bacterialInfections and infestations | 0/331 | 1/327 |
| Blood glucose increasedInvestigations | 0/331 | 1/327 |
| Thrombophlebitis superficialVascular disorders | 0/331 | 1/327 |
| Myocardial infarctionCardiac disorders | 1/331 | 0/327 |
| Escherichia urinary tract infectionInfections and infestations | 1/331 | 0/327 |
| Event | Tedizolid Phosphate | Linezolid |
|---|---|---|
| NauseaGastrointestinal disorders | 26/331 | 36/327 |
| HeadacheNervous system disorders | 20/331 | 22/327 |
| DiarrhoeaGastrointestinal disorders | 11/331 | 17/327 |
| VomitingGastrointestinal disorders | 10/331 | 17/327 |
| AbscessInfections and infestations | 14/331 | 10/327 |
| CellulitisInfections and infestations | 9/331 | 6/327 |
| FatigueGeneral disorders | 8/331 | 7/327 |
| Vulvovaginal mycotic infectionInfections and infestations | 2/331 | 7/327 |
| DizzinessNervous system disorders | 4/331 | 7/327 |
All randomized participants
| Age, Continuous(years) | Tedizolid Phosphate | Linezolid | Total |
|---|---|---|---|
| Mean | 45.6 ± 15.79 | 45.6 ± 15.57 | 45.6 ± 15.67 |
| Sex: Female, Male(Participants) | Tedizolid Phosphate | Linezolid | Total |
|---|---|---|---|
| Female | 107 | 120 | 227 |
| Male | 225 | 214 | 439 |
Showing the first 100 of 118 sites across 11 countries. Choose a country and city above to see the rest.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2011 to primary completion in Jan 2013, 15 months.
Results were first posted in Sep 2014, 1 year 7 months after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedizolid phosphate
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →